Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies

Related Clinical Trial
Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases Building Online Community for Parkinson’s Palliative Care Test-retest Study With [18F]PI-2620 in PSP-RS and NDC Evaluation of the Efficacy of a Two-week EMST on Dysphagia in Parkinsonian Patients Optimization of Morphomer-based Alpha-synuclein PET Tracers Evaluation of [18F]APN-1607 as a PET Biomarker A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) RT001 in Patients With Progressive Supranuclear Palsy (PSP) PROGRESSIVE SUPRANUCLEAR PALSY Complex Eye Movements in Parkinson’s Disease and Related Movement Disorders tDCS and Speech Therapy for Motor Speech Disorders Caused by FTLD Syndromes: a Feasibility Study Application od Machine Learning Method in Validation of Screening Cognitive Test for Parkinsonisms Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA) Remote Monitoring in Progressive Supranuclear Palsy (PSP) Trial of Parkinson’s And Zoledronic Acid Rho Kinase (ROCK) Inhibitor in Tauopathies – 1 UPenn Observational Research Repository on Neurodegenerative Disease Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies The MOTIVE-PSP Initiative A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy Efficacy and Safety of Transcranial dIrect Current stiMulation (tDCS) in Progressive Supranuclear Palsy (PSP) (STIM-PSP) Image Characteristic and Longitudinal Follow up of 18F-PMPBB3 (APN-1607) PET for Progressive Supranuclear Palsy Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy Misfolded Proteins in the Skin of People With Parkinson’s Disease and Other Parkinsonism Neurodegenerative Diseases Registry Transcranial Magnetic Stimulation in Progressive Supranuclear Palsy 18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer’s Disease, Other Dementias and Normal Controls Brain Network Activation in Patients With Movement Disorders Neurologic Stem Cell Treatment Study ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes ADDIA Proof-of-Performance Clinical Study Defining Phenotypes of Movement Disorders :Parkinson’s Plus Disorders (PD), Essential Tremor (ET), Cortical Basal Degeneration (CBD), Multiple Systems Atrophy (MSA), Magnetoencephalography. Gait Analysis in Neurological Disease Diagnosing Frontotemporal Lobar Degeneration Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies Study of the Neural Basis of Analogical Reasoning Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Phase 1 Test-retest Evaluation of [18F]MNI-958 PET Diagnostic and Prognostic Biomarkers in Parkinson Disease Tau Imaging With JNJ067 Research of Biomarkers in Parkinson Disease More Than a Movement Disorder: Applying Palliative Care to Parkinson’s Disease Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism Identifying Biomarkers of Parkinson’s Disease Using Magnetic Resonance Imaging (MRI) Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) Davunetide (AL-108) in Predicted Tauopathies – Pilot Study Robot Walking Rehabilitation in Parkinson’s Disease Human CNS Tau Kinetics in Tauopathies 4-Repeat Tauopathy Neuroimaging Initiative – Cycle 2 In-Home Care for Patients With PSP and Related Disorders Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) Biomarkers in Parkinsonian Syndromes Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain Effects of Coenzyme Q10 in PSP and CBD 2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism Oxford Study of Quantification in Parkinsonism A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects The Neural Basis for Frontotemporal Degeneration Analysis of the Enteric Nervous System Using Colonic Biopsies Evaluation of Tolfenamic Acid in Individuals With PSP at 12-Weeks Chromatic Pupillometry to Assess the Melanopsin-Light Pathway in Progressive Supranuclear Palsy 4 Repeat Tauopathy Neuroimaging Initiative A Study to Assess Tolerability, Safety, Pharmacokinetics and Effect of AZP2006 in Patients With PSP Foot Mechanical Stimulation for Treatment of Gait and Gait Related Disorders in Parkinson’s Disease and Progressive Supranuclear Palsy. Safety Study of TPI-287 to Treat CBS and PSP Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain Neuroprotection and Natural History in Parkinson’s Plus Syndromes (NNIPPS) Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy Pathophysiology of Gait and Posture in Progressive Supranuclear Palsy A Pilot Clinical Trial of Pyruvate, Creatine, and Niacinamide in Progressive Supranuclear Palsy. Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of Parkinsonism tDCS Plus Physical Therapy for Progressive Supranuclear Palsy Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration Risk Factors for Progressive Supranuclear Palsy (PSP) Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy Cerebellar rTMS Theta Burst for Postural Instability in Progressive Supranuclear Palsy Neuropsychological Evaluation for Early Diagnosis of PSP Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer’s, Progressive Supranuclear Palsy Subjects, and Controls A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear Palsy Study of the Distractibility Syndrome in Patients With Progressive Supranuclear Palsy Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003 PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK The Study to Evaluate the Safety and Efficacy of Spinal Cord Stimulation on Progressive Supranuclear Palsy Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy Young Plasma Transfusions for Progressive Supranuclear Palsy Study of BIIB092 in Participants With Progressive Supranuclear Palsy A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP) Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy Deep TMS for the Treatment of Patients With Parkinson’s Disease and Progressive Supranuclear Palsy Rehabilitation in Patients With Progressive Supranuclear Palsy A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy Alpha-lipoic Acid/L-acetyl Carnitine for Progressive Supranuclear Palsy Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP) Quality of Life of the Patient and the Burden of the Caregiver in Progressive Supranuclear Palsy An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP) A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP). Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine) Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy Postural Instability in Progressive Supranuclear Palsy

Brief Title

Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies

Official Title

Phase 0 Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Alzheimer's Disease and Other Tauopathies

Brief Summary

      The overall goal of this imaging trial is to characterize [18F]MNI-815, a PET radioligand for
      imaging Tau.
    


Study Phase

Early Phase 1

Study Type

Interventional


Primary Outcome

Brain uptake of [18F]MNI-815


Condition

Alzheimer's Disease (AD)

Intervention

[18F]MNI-815 (MNI-815)

Study Arms / Comparison Groups

 [18F]MNI-815 (MNI-815)
Description:  At the [18F]MNI-815 PET imaging visit, subjects will be injected with no more than 10mCi of [18F]MNI-815

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

7

Start Date

May 2015

Completion Date

August 2016

Primary Completion Date

July 2016

Eligibility Criteria

        Inclusion Criteria:

        For all subjects:

          -  Written informed consent must be obtained before any assessment is performed.

          -  Female subjects must be either surgically sterile (by means of hysterectomy, bilateral
             oophorectomy, or tubal ligation) or post-menopausal for at least 1 year or, if they
             are child-bearing potential, must commit to use of a barrier contraception method for
             the duration of the study.

          -  Male subjects and their partners of childbearing potential must commit to the use of
             two methods of contraception, one of which is a barrier method for male subjects for
             the study duration

          -  Willing and able to cooperate with study procedures

        Healthy Control subjects:

          -  Males and females aged between 50 - 70 years. Healthy with no clinically relevant
             finding on physical examination at screening and upon reporting for the [18F]MNI-815
             imaging visit.

          -  No cognitive impairment from neuropsychological battery as judged by the investigator

          -  Have a CDR score=0

          -  Has FBB PET imaging demonstrating no evidence for significant amyloid binding based on
             qualitative (visual read) and quantitative analysis.

          -  Modified Hachinski Ischemia Scale score of ≤ 4.

        Prodromal or Moderate Alzheimer's Disease subjects:

          -  Males and females aged between 50 - 90 years.

          -  Have prodromal or moderate Alzheimer's disease, based on the NINCDS/ADRDA and DSM-IV
             criteria.

          -  Have a CDR score of 0.5 for prodromal AD subjects and CDR > 1.0 for moderate AD
             subject at screening.

          -  Has a FBB PET imaging demonstrating amyloid binding based on qualitative (visual read)
             and quantitative analysis.

          -  Modified Hachinski Ischemia Scale score of ≤ 4.

          -  A brain MRI that supports a diagnosis of AD, with no evidence of focal disease to
             account for dementia or MRI exclusion criteria.

          -  Medications taken for symptomatic treatment of AD must be maintained on a stable
             dosage regimen for at least 1 month before the [18F]MNI-815 imaging visit.

          -  The subject has an appropriate caregiver capable of accompanying subject on all
             visits.

          -  Signed and dated written informed consent obtained from the subject and, when
             applicable, the subject's legally authorized representative or caregiver.

        Frontotemporal Dementia subjects:

          -  Has a clinical diagnosis of FTD based on consensus for clinical diagnosis of
             frontotemporal dementia criteria (Neary, et al 1998)

          -  Has a FBB PET imaging demonstrating no evidence of significant amyloid binding based
             on qualitative (visual read) and quantitative analysis.

          -  A brain MRI that supports a diagnosis of FTD, with no evidence of focal disease to
             account for dementia or MRI exclusion criteria.

          -  Medications taken for symptomatic treatment of cognitive dysfunction must be
             maintained on a stable dosage regimen for at least 1 month before the screening visit.

          -  The subject has an appropriate caregiver capable of accompanying subject on all visits
             to the center.

          -  Signed and dated written informed consent obtained from the subject and, when
             applicable, the subject's legally authorized representative or caregiver.

          -  Modified Hachinski Ischemia Scale score of ≤ 4.

        Progressive Supranuclear Palsy subjects:

          -  Has a clinical diagnosis of PSP based the NINDS and Society for PSP criteria (Litvan,
             et al 1996)

          -  Has FBB PET imaging demonstrating no evidence of significant amyloid binding based on
             qualitative (visual read) and quantitative analysis.

          -  A brain MRI that supports a diagnosis of PSP, with no evidence of focal disease to
             account for dementia or MRI exclusion criteria.

          -  Medications taken for treatment of PSP symptoms must be maintained on a stable dosage
             regimen for at least 1 month before the screening visit.

          -  The subject has an appropriate caregiver capable of accompanying subject on all visits
             to the center.

          -  Signed and dated written informed consent obtained from the subject and, when
             applicable the subject's legally authorized representative or caregiver.

          -  Modified Hachinski Ischemia Scale score of ≤ 4.

        Corticobasal Syndrome Subjects:

          -  Has a clinical diagnosis of CBS based on consensus criteria for possible or probable
             corticobasal degeneration (Armstrong et al, 2013)

          -  Has a FBB PET imaging demonstrating no evidence of significant amyloid binding based
             on qualitative (visual read) and quantitative analysis.

          -  A brain MRI that supports a diagnosis of CBS, with no evidence of focal disease to
             account for dementia or MRI exclusion criteria.

          -  Medications taken for treatment of CBS symptoms must be maintained on a stable dosage
             regimen for at least 1 month before the screening visit.

          -  The subject has an appropriate caregiver capable of accompanying subject on all visits
             to the center.

          -  Signed and dated written informed consent obtained from the subject and, when
             applicable, the subject's legally authorized representative or caregiver.

          -  Modified Hachinski Ischemia Scale score of ≤ 4.

        Exclusion Criteria:

        For all subjects

          -  Current or prior history of any alcohol or drug abuse.

          -  Laboratory tests with clinically significant abnormalities and/or clinically
             significant unstable medical illness.

          -  Prior participation in other research protocols or clinical care in the last year such
             that radiation exposure is >15 mSv and would exceed the annual limits.

          -  Pregnancy or breastfeeding.

          -  Evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal,
             hematological, neoplastic, endocrine, alternative neurological, immunodeficiency,
             pulmonary, or other disorder or disease.

          -  Unsuitable veins for repeated venipuncture.

          -  MRI exclusion criteria include: Pathology that may be responsible for the neurologic
             status of the patient such as infectious disease, space-occupying lesions, normal
             pressure hydrocephalus or any other abnormalities associated with CNS disease,

          -  Implants such as implanted cardiac pacemakers or defibrillators, insulin pumps,
             cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS
             aneurysm clips and other medical implants that have not been certified for MRI, or
             history of claustrophobia in MRI.

        Exclusion criteria for subjects with AD subjects:

          -  Has received treatment that targeted amyloid-beta or tau within the last 24 months.

          -  Has a FBB PET imaging demonstrating no evidence of significant amyloid binding
             irrespective of other previous measurements of beta amyloid that may be available for
             review.

        Exclusion criteria for subjects with PSP or CBS subjects:

          -  Has FBB PET imaging with evidence of significant amyloid binding irrespective of other
             previous measurements of beta amyloid that may be available for review.

          -  Has received treatment that targeted tau within the last 24 months.

          -  Have any other neurological condition other than CBS or PSP that could account for
             cognitive or motor deficits including: Specifically:

          -  A diagnosis of idiopathic Parkinson's disease or Lewy body dementia and/or have a
             prominent and sustained response to levodopa therapy;

          -  History of repeated strokes with stepwise progression of parkinsonian features or
             history of major stroke

        FTD subjects:

          -  Has FBB PET imaging with evidence of significant amyloid binding irrespective of other
             previous measurements of beta amyloid that may be available for review.

          -  Has received treatment that targeted tau within the last 24 months.

        Healthy subjects:

        •Has FBB PET imaging with evidence of significant amyloid binding irrespective of other
        previous measurements of beta amyloid that may be available for review.
      

Gender

All

Ages

50 Years - 90 Years

Accepts Healthy Volunteers

Accepts Healthy Volunteers

Contacts

Danna Jennings, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT02531360

Organization ID

MNI-815


Responsible Party

Principal Investigator

Study Sponsor

Molecular NeuroImaging

Collaborators

 Life Molecular Imaging SA

Study Sponsor

Danna Jennings, MD, Principal Investigator, Molecular NeuroImaging, LLC


Verification Date

December 2016